CASI Pharmaceuticals Files 6-K, Incorporates Exhibits
Ticker: CASIF · Form: 6-K · Filed: Dec 23, 2025 · CIK: 1962738
Sentiment: neutral
Topics: reporting, sec-filing, registration
TL;DR
CASI Pharma filed a 6-K on 12/23/25, incorporating exhibits into F-3 filings.
AI Summary
CASI Pharmaceuticals, Inc. filed a Form 6-K on December 23, 2025, reporting for the month of December 2025. The filing incorporates by reference information from Exhibits 99.1 into its Registration Statements on Form F-3, specifically referencing File Numbers 333-283998 and 333-.
Why It Matters
This filing indicates ongoing regulatory and reporting activities for CASI Pharmaceuticals, Inc., potentially related to its ongoing financing or business operations as reflected in its Form F-3 registration statements.
Risk Assessment
Risk Level: low — This is a routine reporting form (6-K) that incorporates previously filed information, not a material event disclosure.
Key Numbers
- 001-41666 — SEC File Number (Identifies CASI Pharmaceuticals, Inc. with the SEC.)
- 20251223 — Filing Date (Date the Form 6-K was filed.)
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Filer of the 6-K report
- 001-41666 (company) — SEC File Number for CASI Pharmaceuticals, Inc.
- 333-283998 (dollar_amount) — File number referenced in Form F-3
- 20251223 (date) — Filing date and period of report
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report for the month of December 2025 and to incorporate by reference information from Exhibits 99.1 into the Company's Registration Statements on Form F-3.
What are the specific Form F-3 registration statement file numbers mentioned?
The filing references Registration Statements on Form F-3 with File Numbers 333-283998 and 333-.
When was CASI Pharmaceuticals, Inc. formerly known as?
The company was formerly known as CASI Pharmaceuticals Holdings, Inc., with a date of name change on January 18, 2023.
Where is CASI Pharmaceuticals, Inc. located?
The company's principal executive office is located at 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, 100025, People's Republic of China.
Does CASI Pharmaceuticals file annual reports under Form 20-F or Form 40-F?
CASI Pharmaceuticals, Inc. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 236 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2025-12-23 16:15:44
Filing Documents
- tm2534203d1_6k.htm (6-K) — 10KB
- tm2534203d1_ex99-1.htm (EX-99.1) — 13KB
- tm2534203d1_ex99-1img001.jpg (GRAPHIC) — 15KB
- 0001104659-25-124228.txt ( ) — 45KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CASI Pharmaceuticals, Inc. By: /s/ David Cory Name: David Cory Title: CEO Date: December 23, 2025